Is the level of glycosaminoglycans in the body too high?

The structure of the human body is relatively complex. In addition to human organs, pathological changes or increases in other cell tissues can easily cause some physical diseases and cause great harm to health. Ganprol aminopeptidase is a kind of human cell tissue. If the body has high levels of Ganprol aminopeptidase, it can easily lead to some physical diseases. Liver cancer can easily lead to high levels of Ganprol aminopeptidase, which is a relatively serious disease.

Is elevated glycosaminoglycan serious?

Elevated levels of glycylproline dipeptidyl aminopeptidase indicate the possibility of liver cancer.

The average serum GPAD activity of patients with primary liver cancer is more than 2 times the reference value, and the average serum GPDA activity of patients with secondary liver cancer is more than 3 times the reference value. In acute hepatitis, serum GPDA is only slightly elevated regardless of the presence or absence of jaundice. Regular review is recommended.

Clinical significance

1. The GPDA activity in the serum of patients with primary liver cancer (PHC) and secondary liver cancer was significantly higher than that of patients with chronic hepatitis, cirrhosis, cholelithiasis, obstructive jaundice and the normal control group. In patients with acute hepatitis, chronic active liver disease, cirrhosis, obstructive jaundice, etc., serum GPDA may increase to varying degrees, but the increase is not as great as that in patients with liver cancer. However, in patients with severe hepatitis and alcoholic hepatitis, serum GPDA may be higher than that in patients with liver cancer. Elevated serum GPDA can exclude the diagnosis of hepatic hemangioma.

2. The serum GPDA of gastric cancer patients is significantly decreased, generally about 1/2 of that of normal people. Other benign gastrointestinal lesions. GPDA may also decline slightly. The largest decrease was in gastric ulcer, followed by chronic gastritis and duodenal bulb ulcer. After gastric cancer resection, the patient's serum GPDA tends to rise.

3. The serum GPDA activity of patients with rheumatoid arthritis (RA) with a disease course of more than 15 months was significantly lower than that of healthy controls, and the enzyme activity was negatively correlated with the length of the disease course.

4. The serum level of patients with systemic lupus erythematosus (SLE) is also significantly reduced, but the enzyme activity is not correlated with clinical manifestations.

5. Serum GPDA is significantly reduced in patients with acute lymphocytic leukemia, lymphosarcoma and Hodgkin's disease.

6. Serum GPDA determination is meaningful for distinguishing benign and malignant liver lesions, monitoring liver metastasis of cancer and detecting gastric cancer.

7. In patients with intrahepatic cholestasis caused by drug-induced liver damage or primary biliary cirrhosis, serum GPDA activity is elevated, which should be paid attention to in clinical applications.

Physiological variation

Using umbilical cord blood as a sample, the serum GPDA activity was measured. The serum GPDA of 65 newborns was significantly lower than that of healthy adults (23 to 76 years old), indicating that the serum GPDA activity gradually increases during the rapid development period from birth to 20 years old. This may be related to the increase in collagen amount and also suggests the role of GPDA in the degradation of collagen peptides. 

The serum GPDA of young men under 40 years old was slightly higher than that of young women (P<0.001); the serum GPDA of women over 40 years old was slightly higher than that of young women under 40 years old (P<0.05), but this was not the case for men.